Previous Article | Next Article 
Infection and Immunity, May 1999, p. 2522-2530, Vol. 67, No. 5
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Towards a Taenia solium Cysticercosis Vaccine: an
Epitope Shared by Taenia crassiceps and Taenia
solium Protects Mice against Experimental
Cysticercosis
Andrea
Toledo,1
Carlos
Larralde,1
Gladis
Fragoso,1
Goar
Gevorkian,1
Karen
Manoutcharian,1
Marisela
Hernández,1
Gonzalo
Acero,1
Gabriela
Rosas,1
Fernando
López-Casillas,2
Carlos Kubli
Garfias,1
Ricardo
Vázquez,1
Ignacio
Terrazas,1 and
Edda
Sciutto1,*
Department of Immunology, Instituto de
Investigaciones Biomédicas,1 and
Instituto de Fisiología
Celular,2 UNAM, México D.F. 04510, México
Received 14 August 1998/Returned for modification 7 October
1998/Accepted 14 January 1998
 |
ABSTRACT |
The Taenia crassiceps recombinant antigen KETc7 has
been shown to be effective as a vaccine against experimental
murine cysticercosis, a laboratory model used to test potentially
promising molecules against porcine Taenia solium
cysticercosis. Based on the deduced amino acid sequence of this
proline-rich polypeptide, three fragments, GK-1, GK-2, and GK-3, were
chemically synthesized in linear form. Of the three peptides, only GK-1
induced sterile protection against T. crassiceps
cysticercosis in 40 to 70% of BALB/cAnN male mice. GK-1 is an
18-amino-acid peptide which contains at least one B-cell epitope, as
demonstrated by its ability to induce an antibody response to the
peptide and T. crassiceps antigen without need of a
carrier protein. Immunofluorescence studies revealed that anti-GK1
antibodies strongly react with the native protein in the tegument of
T. crassiceps and also with anatomical structures of
T. solium eggs, oncospheres, cysticercus, and
tapeworm. GK-1 also contains at least one T-cell epitope, capable of
stimulating the proliferation of CD8+ and to a lower extent
CD4+ T cells primed either with the free peptide or
T. crassiceps total antigen. The supernatant of the
stimulated cells contained high levels of gamma interferon and low
levels of interleukin-4. Similar results were obtained with T cells
tested for intracellular cytokine production, an indication of the
peptide's capacity to induce an inflammatory response. The remarkable
protection induced by GK-1 immunization, its physicochemical
properties, and its presence in all developmental stages of
T. solium point to this synthetic peptide as a strong
candidate in the construction of a synthetic vaccine against
T. solium pig cysticercosis.
 |
INTRODUCTION |
Taenia solium
cysticercosis is highly prevalent in humans and pigs in Latin America,
Asia, and Africa (24) and has serious health and economic
consequences (10). Although cysticercosis has been
practically eradicated in developed countries, it is a major concern in
the developing world and of consideration as a reemerging disease in
the United States because of immigration from areas where the disease
is endemic (20). Moreover, a recent publication indicates
that European countries may not be totally rid of human
neurocysticercosis caused by T. solium (26).
The life cycle of this parasite includes a larval (cysticercus) phase affecting both pigs and humans after ingestion of eggs present in human
feces. The eggs are produced by the adult tapeworm localized in the gut
of humans who ingested live cysticerci present in improperly cooked
pork meat. The tapeworm produces millions of eggs that are passed to
the environment. Transmission is thus clearly related to prevailing low
sanitary standards in personal hygiene and environmental control and
also with rustic rearing of pigs in impoverished sectors of the rural
population. Control of transmission by general improvement of the
social, economic, and educational status of developing countries is not
within reach in the near future. But since the pig is an indispensable
intermediate host, transmission could be reduced by lowering the
prevalence of pig cysticercosis through vaccination. Development of an
effective vaccine for use in pigs is being pursued by a number of
scientists (14, 16, 23).
Because experimentation leading to a vaccine against porcine
cysticercosis is hampered by the high cost and slow data retrieval involved in testing pigs, another cestode, Taenia
crassiceps, which exhibits extensive antigen similarities with
T. solium and whose metacestodes easily and rapidly
develop in the peritoneal cavity of mice (3, 7, 10), has
been used as an experimental model to test and screen promising
antigens before testing them in pigs (11, 12, 22, 28). Thus,
we have shown that total T. crassiceps antigens can
partially protect pigs against T. solium cysticercosis:
however, the effects of vaccination with antigen extracts depended on
the dose used, some being protective while others led to facilitation
of the infection (23), a finding that oriented our research
to the identification of individual protective antigens and their
peptidic epitopes (11, 12, 28). We identified and cloned
four recombinant T. crassiceps antigens (KETc1, -4, -7, and -12) which conferred to mice different levels of resistance to
murine cysticercosis (12). The antigenicity profile of
the deduced 100-amino-acid sequence of the KETc7 clone was structurally
assessed to detect potentially immunologically active epitopes
(8). Three of the peptide candidates of KETc7 (GK-1, GK-2,
and GK-3) were chemically synthesized, and their antigenicity was
tested with sera from T. solium- and T. crassiceps-infected hosts (humans, pigs, and mice). Since the
three peptides were extensively reactive with these sera
(8), we assessed their protective capacity and studied the
immune response that they elicit in immunized mice. We also searched
for the peptide's presence in T. solium specimens to
obtain indications as to its potential inclusion in a vaccine against
porcine cysticercosis, especially if found in oncospheres and early
larvae, the parasite's developmental stages most vulnerable to
immunological attack by antibodies (17). Also, the
peptide's physicochemical properties and structural characteristics
were studied to understand its immunological functions.
 |
MATERIALS AND METHODS |
Peptides.
The peptides GK-1 (amino acids [aa] 69 to 85;
GYYYPSDPNTFYAPPYS[A]), GK-2 (aa 55 to 66;
[KK]MPPYPTGGPPPV[K]), and GK-3 (aa 35 to 50;
PPYAPNPGPPPPYTGA) were manually prepared by stepwise solid-phase synthesis with N-tert-butyloxycarbonyl
derivatives of L-amino acids on phenylacetamidomethyl resin
(Sigma Chemical Co., St. Louis, Mo.). All peptides were 95% pure as
judged by high-pressure liquid chromagraphy on analytical
C18 reversed-phase columns (3.9 by 150 mm; Delta Pak;
Waters). The correct amino acid sequence of each peptide was confirmed
by protein sequencing on a pulsed-liquid-phase protein sequencer
(Applied Biosystems) at the National Institute of Cardiology, Mexico
City, Mexico. GK-1 was coupled to bovine serum albumin (BSA) by
standard procedures (25) using glutaraldehyde. Also, GK-1
was prepared as MAP (multiple-antigen peptide), containing eight copies
of the GK-1 sequence coupled to a core matrix comprising oligomeric
lysine (25).
Mice.
A syngenic BALB/cAnN strain of mice, previously
characterized as susceptible to cysticercosis (22), was used
for vaccine trials. Original stocks were purchased from M. Bevan
(University of Seattle) and then bred and kept in our animal facilities
by the single-line breeding system for 20 generations. All mice used were males of 5 to 7 weeks of age at the beginning of the experiments. The experiments reported herein were conducted according to the principles set forth in the Guide for the Care and Use of
Laboratory Animals (1a).
Immunization of mice and collection of sera.
Groups of 5 to
10 BALB/cAnN mice each were immunized subcutaneously with different
doses (0.5, 10, and 50 µg/mouse) of each peptide (GK-1, GK-2, and
GK-3) emulsified in Freund's complete adjuvant (FCA) prepared as
previously reported (28). GK-1 (10 µg/mouse) as well as
MAP-GK-1 and BSA-GK-1 (each at 50 µg/mouse) were prepared in
saponin (Sigma) at a concentration of 100 µg/mouse as reported
elsewhere (13). This concentration of peptide was determined
as optimal when saponin was used as the adjuvant in collateral
experiments (data not shown). Ten days later, the mice were given a
booster with the same immunizing dose of the same peptide in the same
adjuvant as used before. Immune sera were obtained from each mouse
before each immunization and stored at
70°C until individually
tested for the presence of specific antibodies.
Parasites.
The ORF strain of T. crassiceps
(Zeder 1800) Rudolphi 1810, isolated by Freeman in 1962 (7)
and supplied by B. Enders (Behringwerke, Marburg, Germany) in 1984 has
been maintained by serial passage in BALB/cAnN female mice for 14 years
in our animal facilities. Cysticerci for infection were harvested from
the peritoneal cavity of mice 1 to 3 months after inoculation of 10 nonbudding small cysticerci (2 to 3 mm in diameter) per animal. Whole
T. solium cysticerci were dissected from skeletal
muscle of highly infected pork carcasses between 2 and 4 h after
slaughter in an abattoir in Zacatepec, Morelos, Mexico. Segments from
T. solium tapeworm and eggs were obtained from the
feces of an infected child in the state of Puebla, Mexico. The tapeworm
was recovered after the child's treatment with a single oral dose (2 g) of niclosamide (Yomesan; kindly supplied by Bayer, Mexico City,
Mexico). After washing in saline plus antibiotics (penicillin
[100 U/per ml] plus streptomycin [100µg/ml]) streptomycin),
several gravid proglottids were separated for immunofluorescence
assays; eggs were obtained by cutting the proglottids with fine sharp
scissors and then teasing the fragments. The eggs were then washed in
saline before inclusion to immunolocalization studies.
T. crassiceps cysticercal antigens.
Soluble
antigens were recovered from T. crassiceps cysticerci
by the procedure previously described (9). Briefly,
cysticerci recovered 1 to 3 months after infection were collected and
placed in ice-cold phosphate-buffered saline (PBS). Cysticerci were
then suspended in a minimal amount of buffer and centrifuged at 25,000 rpm for 60 min at 4°C. Afterwards, the cysts were ruptured by centrifugation, and the supernatant, which included the mixture of
soluble T. crassiceps antigens, was recovered.
ELISA for antibody measurements.
T. crassiceps
antigens obtained as previously described (10) were used as
antigens in enzyme-linked immunosorbent assay (ELISA) to measure the
antibody response induced by peptide immunization as described
elsewhere (19). Briefly, 96-well flat-bottomed microtitration plates (Nunc, Roskilde, Denmark) were coated with the
respective antigen preparation (1 µg/per well) and incubated overnight at 4°C. Sera were used at 1:100 dilution in PBS containing 1% BSA. Bound mouse immunoglobulins (Igs) were detected by using alkaline phosphatase-conjugated sheep anti-mouse IgG (whole molecule; Sigma) diluted 1:1,000 for 1 h at 37°C. The substrate used was detected by using p-nitrophenyl phosphate (Sigma) in
diethanolamine buffer for 10 min at room temperature. The reaction was
stopped with 2 N NaOH. Readings of optical density at 405 nm
(OD405) were carried out in a Humareader ELISA processor
(Human Gessellschaft Für Biochemica und Diagnostica, Taunusstein, Germany).
Proliferation assay.
Spleen cells from nonimmunized
(injected only with saponin) or GK-1-immunized mice were harvested 15 days after the second immunization with saponin or GK-1 plus saponin,
respectively, and cultured in RPMI 1640 medium supplemented with
L-glutamine (0.2 mM), nonessential amino acids (0.01 mM),
penicillin (100 U/ml), streptomycin (100 µg/ml), and fetal bovine
serum (FBS; 10%). Cells were cultured with the appropriate
concentration of concanavalin A (CoA) (5 µg/ml) or GK-1 or
T. crassiceps antigens (10 µg/ml) and incubated at
37°C in a 5% CO2 humidified atmosphere, in flat-bottomed
microtiter plates, at a cell concentration of 2 × 105
per 200 µl of final volume. Considering previous results in which higher levels of proliferation were obtained when peritoneal cells were
included in the assay (data not shown), 104 peritoneal
cells recovered from the same mice were added to each well at a volume
of 50 µl. Peritoneal cells were obtained by ex vivo lavage with 5 ml
of RPMI 1640. The cells were sedimented by centrifugation at
800 × g for 10 min. The pellets were resuspended in an
additional 3 ml of supplemented RPMI 1640 medium and adjusted in volume
to contain 2 × 105 cells/ml. After 72 h, the
cultured cells were pulsed (1 µCi per well) for a further 18 h
with [methyl-3H]thymidine (Amersham Life
Science, Little Chalfont, England). Then all cells were harvested, and
the amount of incorporated label was measured by counting in a model
1205
-plate spectrometer (Wallac). All assays were performed in
triplicate with at least four individual mice.
Spleen cell phenotype analysis.
After 3 days of in vitro
culture with different doses of mitogen, antigen, or peptide,
splenocytes were harvested and CD8/CD25 and CD4/CD25 expression was
determined by staining with two-color cytometry using fluorescein
isothiocyanate (FITC)-conjugated anti-CD8 (Pharmingen, San
Diego, Calif.), FITC-conjugated anti-CD4 (Pharmingen), and
phycoerythrin (PE)-conjugated anti-CD25. The percentage of CD3+ cells was determined by single-color cytometry
using FITC-conjugated anti-CD3 (Boehringer, Mannheim, Germany) as
previously described (6). Parallel samples of the cells were
stained with the corresponding isotype control to account for
nonspecific staining of the cells. Briefly, cells were washed with PBS
containing 10% of gamma globulin-depleted FBS plus 0.02%
NaN3 and incubated with the indicated antibodies at 4°C
for 30 min. After washing, splenocytes were resuspended in cold 3%
formaldehyde in isotonic solution and analyzed by FACScan (Becton
Dickinson, Palo Alto, Calif.). Results were expressed as percentage of
positive cells.
Cytokine measurements.
Supernatant from spleen cells
described above were harvested after 72 h. The solid-phase ELISAs
for measurement of interleukin-4 (IL-4) and gamma interferon (IFN-
)
were used as previously described (27) and as instructed by
the manufacturer (Pharmingen). The pairs of cytokine-specific
monoclonal antibodies and recombinant cytokines were all obtained from Pharmingen.
For the detection of intracellular cytokines in spleen cells treated
with medium, GK-1 or T. crassiceps antigens were
cultured for 60 h. To inhibit cytokine secretion, brefeldin A (2 µM) was added to cell cultures 10 h before the assay. At
harvest, the cells were centrifuged at 500 × g for 10 min and washed twice in ice-cold PBS containing 10% globulin-depleted
FBS plus 0.02% NaN3. CD3 and interleukin expression was
determined by two-color fluorescence-activated cell sorting (FACS) as
previously described (4). Briefly, cells were stained with
the FITC-conjugated anti-CD3 monoclonal antibody (Pharmingen).
Intracellular cytokines were assayed by using a cytoStain TM kit
(Pharmingen) to fix and permeabilize the cells. To stain intracellular
cytokines, fixed and permeabilized cells were incubated with monoclonal
rat anti-IL-2-PE, anti-IL-4-PE, anti-IL-10-PE, or anti-IFN-
-PE
(all from Pharmingen). Parallel samples of the cells were stained with
an isotype control to account for nonspecific staining of the cells.
Ten thousand cells were analyzed with a CD3+ lymphocyte
gate as defined by light scatter in a FACScan (Becton Dickinson). The
percentage of cells in each quadrant is indicated in the dot plot.
Quadrant statistics were set on the basis of the corresponding isotype controls.
Experimental challenge.
Metacestodes used in challenge
infections were harvested from BALB/cAnN female mice carrying the ORF
strain of T. crassiceps cysticerci. Ten small (diameter
of ca. 2 mm), nonbudding larvae were suspended in 0.5 M NaCl-0.01 M
sodium phosphate buffer (pH 7.2) and injected intraperitoneally into
each mouse, using a 27-gauge needle. Mice were killed 30 days after
infection, and the cysts found inside the peritoneal cavity were
counted. In this form of infection, the parasites do not migrate to
another location in the host. We attribute variation in individual
parasite intensities within groups to differences in the infectivity of
each parasite inoculum, which also varies between the different
parasite harvests used in challenge infection. In consequence,
experimental designs measuring levels of immunity by parasite intensity
must include in each vaccination session a session-specific measurement
of each inoculum infectivity in nonvaccinated control mice.
Immunolocalization of GK-1 protein.
T. crassiceps
cysticerci and T. solium specimens (cysticerci, eggs,
and tapeworm segments) were placed on ice into a 50-ml conical
plastic-bottom centrifuge tube with ice-cold PBS. The vesicular fluid
was removed from cysticerci by slicing the cyst walls and letting the
fluid drain into a sterile centrifuge tube and stored in the cold
(4°C) until use. The tissues were then incubated for 30 s with
glycine-chloride buffer (50 mM glycine-HCl [pH 2.5], 0.1% Triton
X-100, 0.15 mM NaCl) to reduce contamination of host protein, and the
pH was restored by adding Tris-HCl (pH 9). After further washing,
tissues were included in Tissue-Tek O.C.T. compound (Miles, Inc.),
frozen at
70°C, and sectioned 6 µm thick. Sections were placed on
poly-L-lysine-treated microslides, air dried for 30 min,
fixed in acetone for 10 min, and dried for 15 min at room temperature.
The slides were rehydrated and blocked with 1% BSA in PBS plus 0.1%
Triton X-100 (pH 7.2) for 1 h. In cysticercal tissue sections, a
second blocking was performed with sheep anti-mouse IgG (whole
antibody; Amersham) diluted 1:100 in PBS plus 0.1% BSA and incubated
for 1 h at 4°C. Slides of T. solium tapeworms
and eggs were incubated for 1 h at 4°C with horse serum diluted
1:100 in PBS plus 0.1% BSA as a second blocking agent. Solutions were
removed, and the slides were overlaid with the appropriate sera
(diluted 1:10,000 in PBS-0.1% BSA) from noninfected (negative
control), T. crassiceps-infected (positive control), or
anti-GK1-immunized mice, incubated overnight at 4°C, and then washed
twice in PBS (pH 7.2). Finally, sections were incubated with
FITC-labeled goat anti-mouse IgG (Zymed, San Francisco, Calif.) diluted
1:50 for 1 h at room temperature. Slides were washed twice and
mounted with Aquatek polyvinyl alcohol (Merck, Darmstadt, Germany).
Preparations were observed with an Olympus BH2-RFCA epifluorescence microscope.
Statistical analysis.
Statistical comparison of individual
parasite intensities between groups was performed by the Wilcoxon
ranked sum test, because many mice in the immunized groups bore no
parasites and because parasite intensity is a discontinuous variable
(i.e., 0, 1, 2, ... n parasites). Data were considered
statistically significant at P < 0.05. Statistical
analysis of the difference between mean values of binding activity in
ELISA, flow cytometry, and proliferation assays was carried out by
Welch's unpaired t test (alternative t test).
All statistical analyses were performed by the Instat software program
(GraphPad, San Diego, Calif.).
Computational methods in peptide structural analysis.
Theoretical chemistry calculations of GK-1 started with optimization of
its geometry by methods based on molecular mechanics (1).
Subsequently, the peptide was submitted to a single-point calculation
with the Austin model 1 semiempirical quantum chemistry method
(2). In this way, the electrostatic charges, electron density, electrostatic potentials, and dipole moment of the molecule were obtained. Additionally, the log octanol/water partition
coefficient and distributed hydrophobicity of GK-1 were calculated. The
software used consisted of SPARTAN 4.0 (Wave Function Inc., Irvine,
Calif.), Insight II (Biosym/MSI, San Diego, Calif.), and Chem Plus
(Hypercube, Inc., Ontario, Canada).
 |
RESULTS |
Protective effect of peptide immunization against T. crassiceps cysticercosis.
The effects of peptide
immunization on the number of cysticerci recovered from mice immunized
with GK-1, GK-2, and GK-3 at different doses (0.5, 10, and 50 µg per
mice) in FCA are shown in Table 1.
Immunization with the GK-2 and GK-3 peptides did not confer protection,
whereas three of five mice immunized with GK-1 were completely
protected at a dose of 50 µg per mice. To further evaluate this
protective capacity, free GK-1 as well as BSA-GK-1 and MAP-GK-1
emulsified in saponin were used for immunization in several repeated
experiments. Table 2 confirms, in several instances, the high level of protection induced by GK-1 when used as an
immunogen either free of carrier or conjugated to BSA. Mice immunized
with MAP-GK-1 did not show reduced mean parasite intensity, although
some mice were totally protected.
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Effects of immunization with three immunogenic peptides
from T. crassiceps recombinant protective antigen
KETc7 on individual parasite intensities
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Protective immunity against murine T. crassiceps cysticercosis by immunization with cysticercal
antigens and different forms of GK-1
|
|
Determination of B-cell epitope(s) on GK-1.
To test for the
presence of a B-cell epitope(s) on the GK-1 peptide, we studied whether
GK-1 immunization induced antibodies against the peptide and against
whole T. crassiceps antigen by ELISA. Mice immunized
with the monomeric nonconjugated form of GK-1 produced low but
detectable levels of serum antibodies that reacted with GK-1 as well as
with T. crassiceps in ELISA (Table 3). The examination of anti-GK-1
antiserum reactivity against histological sections of T. crassiceps revealed that these antibodies specifically react with
T. crassiceps cysticerci at the tegument of the
parasite. Furthermore, the anti-GK-1 antisera also reacted with all
developmental stages of T. solium (Fig.
1). A clear reaction was detected in the oncosphere contained inside the eggs and also in
the egg wall. In T. solium cysticerci the reacting
protein is concentrated in the spiral canal, while in the tapeworm it is located throughout the distal tegument. The specificity of all of
these antibody reactions in ELISA and immunofluorescence was
demonstrated by specific preabsorption of antisera with free GK-1 and
lack of reactivity of normal mouse serum.

View larger version (58K):
[in this window]
[in a new window]
|
FIG. 1.
Immunofluorescence staining of T. crassiceps (A) and T. solium (B and C) cysticerci
and of eggs (D) and adult tegument (E) of T. solium,
incubated with sera from normal mice (a), 30-day T. crassiceps-infected mice (b), and pooled sera obtained 15 days
after the booster of GK-1 (c). The labeled epitope is clearly evident
in structures accessible to the immune system. It is intensively
expressed in the tegument (T) of T. crassiceps
cysticerci (A, panel c) and weakly in the T. solium
cysticerci (B, panel c). It is strongly expressed in the cuticular
folds of the spiral canal (SC) (C, panel c), in the oncosphere (O) (D,
panel c), and in the distal tegument (T) of the tapeworm (E, panel c).
The arrowheads (C, panel c) indicate the protonehridia. Bars = 40 µm.
|
|
Assessment of T-cell epitopes on the GK-1 peptide.
To identify
the presence of a T-cell epitope(s) on the GK-1 peptide, we studied the
proliferative response of spleen cells from mice treated with GK-1 or
saponin alone. Spleen cells from mice injected in vivo with free
peptide or saponin were stimulated in vitro with the same peptide (10 µg/ml), with T. crassiceps whole antigen (10 µg/ml), or with ConA (5 µg/ml) as a positive control.
Results show that in vitro stimulation with GK-1 as well as with
cysticercal antigens induced a strong proliferative response in
cells from GK-1 immunized mice (Fig. 2).
Cells from mice injected with saponin (nonimmunized mice) showed no
proliferative response above background levels. These results confirm
the presence in GK-1 of T-cell epitope(s).

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 2.
T-cell proliferative response of spleen cells from
nonimmunized (injected with saponin alone) and immunized mice
determined by [3H]thymidine incorporation on day 3 of
culture. Data presented are means ± standard deviations for four
individual mice separately assayed. Cytokine (IFN- and IL-4)
production was determined in collected cultured supernatant obtained
72 h poststimulation. Data are the means for four mice and are
representative of two experiments performed in duplicate. Significantly
increased proliferative response and IFN- levels were achieved when
cells from immunized mice were stimulated both with T. crassiceps antigens and GK-1 peptide.
|
|
As Table
4 shows, the proportion of
CD3
+ T cells from GK-1-immunized mice increased from 39.9 to 58.7 or 54.7% and the proportion
of CD8
+ cells
increased from 12.2 to 19.3 or 20.4% when cells were activated
with
GK-1 or antigen, respectively. The proportion of CD4
+
cells increased only from 28.3 to 32.6 or 32.7%. Interestingly,
most
of the T-stimulated cells (CD8
+ and CD4
+)
from immunized mice were also CD25
+.
Next, we determined the level of secreted cytokines in the
supernatant of in vitro-stimulated spleen cells. Splenocytes from
nonimmunized control mice produced a small amount of IL-4
and
IFN-

that increased only after stimulation with ConA.
In contrast,
a clearly increased amount of IFN-

and a low
amount of IL-4 were
found after stimulation of the splenocytes of
GK-1-immunized mice
both with GK-1 and with whole cysticercal
antigens (Fig.
2). The
frequency of cells capable of producing IL-4,
IFN-

, IL-2, and
IL-10 was also determined by FACS after
intracellular staining
for cytokines. The increased percentage of cells
producing IFN-
and IL-4 determined by FACS was found to be
consistent with ELISA
analysis of the supernatants. Figure
3 shows that frequencies
of cells
producing IFN-

and IL-2 were significantly higher among
T. crassiceps antigen- or GK-1-stimulated cells from
immunized
mice than among cells from nonimmunized mice; levels of IL-4
and
IL-10 were also increased, albeit to lesser extents.

View larger version (45K):
[in this window]
[in a new window]
|
FIG. 3.
Spleen lymphocytes from nonimmunized (injected with
saponin alone) and GK-1-immunized mice 60 h poststimulation were
analyzed for intracellular cytokines (IFN- and IL-4 [A] and IL-2
and IL-10 [B]) and surface CD3+ staining by FACS. Cells
had been dually stained with FITC (abscissa) and PE (ordinate). The
percentage of cells in each quadrant of the dot plot is indicated. The
data are representative of three experiments using different mice.
|
|
GK-1 physicochemical properties.
The dipole moment was
directed toward the tyrosine end of GK-1. The octanol/water partition
coefficient of the peptide was 7.92. However, its hydrophobicity was
distributed in zones in accordance with the amino acid composition.
Thus, the phenylalanine region was the most hydrophobic, while alanine
was the most hydrophilic and the glycine end was more hydrophobic than
the tyrosine end. Planar rings from the tyrosine and phenylalanine
showed high electron density. However, the higher electron density was
observed for the oxygen atoms belonging to the carbonyl and hydroxy
functional groups. Interestingly, the electrostatic potentials were
displayed emerging mostly from these functional groups. Figure
4 shows the physicochemical properties of
GK-1.

View larger version (49K):
[in this window]
[in a new window]
|
FIG. 4.
(a) Amino acid arrangement of GK-1 and its optimized
geometry. The red arrow shows the dipole moment pointing the vector's
negative end toward tyrosine. (b) Space-filling model of GK-1, showing
different degrees of hydrophobicity (red) or hydrophilicity (blue). (c)
The encoded electronic density elicited by the molecule and its
calibration bar at the right, where oxygen atoms display red while
negative zones corresponding to lone pairs of electrons in atoms show
as yellow. (d) The bulk of electrostatic potential emerging mostly from
the negative zones of the electron density surface.
|
|
 |
DISCUSSION |
High levels of sterile immunity to experimental T. crassiceps cysticercosis were conferred to male mice immunized
with a synthetic 18-amino-acid peptide (GK-1) from the recombinant
protein KETc7 of the parasite (12). The proportion of
totally protected mice varied in experiments performed on different
occasions from 40 to 70%, while the average decrement in the immunized
group's parasite intensity was 85 to 95% of that expected from
challenged control male mice. Variation in parasite intensity within
experimental groups and between experimental sessions is a common
finding in this form of cysticercosis due to factors not fully
identified but that we attribute to variation in infectivity of each
parasite harvest and inoculum. The statistical validity of the
inferences drawn from these experiments is, however, not weakened if
each experimental session includes its own internal control. Coupling of GK-1 to BSA or rearranging the peptide in an eight-pointed MAP
construct did not result in an increased immunogenicity of the
peptide and may in fact have reduced it somewhat.
Sterile immunity is seldom induced in this form of cysticercosis by
purified, natural, or recombinant antigens (10, 22, 28);
however, GK-1 induced levels of protection higher than those observed
with the whole KETc7 recombinant protein published elsewhere
(12). Research into the reasons why this peptide is so
effective relative to other forms of antigen preparation, including the
complete recombinant antigen KETc7 from which the peptide is derived
(12), could perhaps reveal general principles of immunogenicity applicable to this and other vaccine preparations. Assuming that the binding properties of GK-1 to antibodies and cellular receptors relate to its immunogenicity, and since
these depend on its stereoelectronic properties, the high dipole
moment and the asymmetry in the electronic distribution of GK-1
are noteworthy. Moreover, GK-1 showed high hydrophobic areas
alternating with hydrophilic ones (Fig. 4b); this dual
hydrophilic-hydrophobic property offers interesting possibilities of
water and lipid interaction that may facilitate the peptide's reaction
with B and T membrane-bound receptors. The external distribution of the
hydroxyl groups favors water or hydrogen bonding, judging from the rich
and complex electrostatic potential of these hydrophilic groups, while
the abundance of aromatic amino acids in GK-1 defines steric regions
with high noncovalent electrostatic interactions capable of enhancing
binding affinity that could also favor the peptide presentation by
antigen-presenting cells (18). The alteration of peptide
immunogenicity by the structural changes imposed by chemical coupling
to BSA and the MAP construction also points to a strong structure
dependence of its biological functions. GK-1's electronic polarity,
adequately positioned anchor motifs, and similarities to motifs
reactive with class I major histocompatibility complex molecules may
explain the peptide's ability to induce a CD8+
proliferative response (18). The involvement of a B-cell
response after immunization is documented by the presence of
serum-specific anti-GK-1 antibodies in immunized mice. Immune
reactivity against the whole-parasite antigens was greater than that
against the GK-1 peptide itself, probably because of loss of reactivity
of GK-1 once bound to the plate. T-cell involvement is shown by the in
vitro proliferative assays with spleen cells from GK-1-immunized mice,
which strongly responded to both GK-1 and cysticercal antigens probably
favored by the increased percentage of T cells producing IL-2. The
composition of the resultant lymphocyte population was most
significantly enriched in CD8+ cells. Although the direct
participation of a cytotoxic response in the control of the parasite's
reproduction remains to be thoroughly elucidated, the immune response
elicited by this peptide features a prominent CD8+ T-cell
response. Other factors contributing to parasite damage may be related
to IFN-
, a cytokine that plays a central role in cell-mediated
effector mechanisms in the protection observed in mice vaccinated
against other parasites (5). The large amount of IFN-
detected by ELISA, as well as the increased percentage of
CD3+ cells that produced this cytokine, could induced the
inflammatory response and the activation of macrophages at the
parasite's vicinity (15). All of these data are also
consistent with the low levels of antibodies induced by GK-1
immunization, which can be the consequence of low levels of IL-4 and
IL-10. As Table 4 shows, the existence of a specific T-cell response in
GK-1-immunized mice and not in those immunized with saponin alone was
also demonstrated by the increased expression of a cell surface
activation marker (CD25+) following antigen- or
peptide-specific reactivation in vitro. The immune protection induced
by GK-1 immunization and the polarized cytokine phenotype induced are
in keeping with recent trends in opinion about immune resistance to
metacestode diseases, which place Th1 cells in the forefront of
protection (27), and add to well-established views that
stress the role of antibody only in the destruction of early larvae
developing from egg infection (21). These two mechanisms
are, of course, not incompatible, and GK-1's high protective
efficiency may well result from the synergic action of its capacity to
trigger both B- and T-cell immune responses.
Another feature of GK-1 that deserve mention is that it is represented
in an antigen fraction of 56 kDa in T. crassiceps
cysticerci which induces high levels of protection against
T. solium pig cysticercosis (28). This GK-1
peptide is also recognized by sera from T. solium-infected humans (8). Furthermore, the
identification of GK-1 by immunofluorescence at all stages of
T. solium
infecting egg, hexacanth embryo,
metacestode, and tapeworm
make GK-1 a likely effective target
for immune attack and an interesting candidate for a vaccine against
T. solium cysticercosis.
 |
ACKNOWLEDGMENTS |
This investigation was supported by Dirección General de
Asuntos de Personal Académico IN208395 and IN212798, Universidad Nacional Autónoma de México, and CONACYT G25955m,
México, Fundación Miguel Alemán.
We thank Felipe Massó for performing the peptide sequence
analysis, Nelly Villalobos for obtaining the T. solium
tapeworm, and Carlos Castellanos and Mercedes Baca for technical
support. Isabel Pérez Montfort aided in translation of the manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Departamento de
Inmunología, Instituto de Investigaciones Biomédicas, UNAM,
A.P. 70228, México D.F., 04510 México. Phone: (5) 6223818. Fax: (5) 6223369. E-mail: edda{at}servidor.unam.mx.
Editor:
J. M. Mansfield
 |
REFERENCES |
| 1.
|
Burkert, U., and N. L. Allinger.
1982.
Molecular mechanics. ACS monograph.
American Chemical Society, Washington, D.C.
|
| 1a.
|
Committee on Care and Use of Laboratory Animals.
1996.
Guide for the care and use of laboratory animals.
Institute of Laboratory Animal Resources, National Research Council, Washington, D.C.
|
| 2.
|
Dewar, M. J. S.,
E. G. Zoebisch,
E. F. Healy, and J. P. Stewart.
1985.
AM1: a new general purpose quantum mechanical molecular model.
J. Am. Chem. Soc.
107:3902-3909.
|
| 3.
|
Dorais, F. J., and G. W. Esch.
1969.
Growth rates of two Taenia crassiceps strains.
Exp. Parasitol.
25:395-398[Medline].
|
| 4.
|
Elson, L. H.,
T. B. Nutman,
D. D. Metcalfe, and C. Prussin.
1995.
Flow cytometric analysis for cytokine production identifies Th1, Th2 and Th0 cells within the human CD4+ CD27 lymphocyte subpopulation.
J. Immunol.
154:4294-4301[Abstract].
|
| 5.
|
Ferru, Y.,
B. Georges,
J. Estaquier,
M. Delacre,
D. A. Harn,
A. Tartar,
A. Capron,
H. Grassmasse, and C. Auriault.
1997.
Analysis of the immune response elicited by a multiple antigen peptide (MAP) composed of two distinct protective antigens derived from the parasite Schistosoma mansoni.
Parasite Immunol.
19:1-11[Medline].
|
| 6.
|
Fragoso, G.,
E. Lamoyi,
A. Mellor,
C. Lomeli,
M. Hernández, and E. Sciutto.
1998.
Increased resistance to Taenia crassiceps murine cysticercosis in Qa-2 transgenic mice.
Infect. Immun.
66:760-764[Abstract/Free Full Text].
|
| 7.
|
Freeman, R. S.
1962.
Studies on the biology of Taenia crassiceps (Zeder, 1800) Rudolphi, 1810 (Cestoda).
Can. J. Zool.
40:969-990.
|
| 8.
|
Gevorkian, G.,
K. Manoutcharian,
C. Larralde,
M. Hernández,
J. C. Almagro,
M. Viveros,
J. Sotelo,
E. Garcia, and E. Sciutto.
1996.
Immunodominant synthetic peptides of Taenia crassiceps in murine and human cysticercosis.
Immunol. Lett.
49:185-189[Medline].
|
| 9.
|
Larralde, C.,
R. M. Montoya,
E. Sciutto,
M. L. Díaz,
T. Govezensky, and E. Coltorti.
1989.
Deciphering Western blots of tapeworm antigens (T. solium, E. granulosus and T. crassiceps) reacting with sera from neurocysticercosis and hydatidic disease patients.
Am. J. Trop. Med. Hyg.
40:282-290.
|
| 10.
|
Larralde, C.,
A. Padilla,
M. Hernández,
T. Govezensky,
E. Sciutto,
G. Gutiérrez,
R. Tapia-Conyer,
B. Salvatierra, and J. Sepúlveda.
1992.
Seroepidemiología de la cisticercosis en México.
Salud Pública Méx.
34:197-210[Medline].
|
| 11.
|
Manoutcharian, K.,
C. Larralde,
A. Aluja,
G. Fragoso,
G. Rosas,
M. Hernández,
N. Villalobos,
L. F. Rodarte,
T. Govezensky,
M. Baca, and E. Sciutto.
1995.
Advances in the development of a recombinant vaccine against Taenia solium pig cysticercosis, p. 63-68.
In
R. M. Chanock, F. Brown, H. S. Ginsberg, and E. Norrby (ed.), Vaccines 95. Cold Spring Harbor, Laboratory, Cold Spring Harbor, N.Y.
|
| 12.
|
Manoutcharian, K.,
G. Rosas,
M. Hernández,
G. Fragoso,
A. Aluja,
N. Villalobos,
L. F. Rodarte, and E. Sciutto.
1996.
Cysticercosis: identification and cloning of protective recombinant antigens.
J. Parasitol.
82:250-254[Medline].
|
| 13.
|
McColm, A. A.,
R. Bomford, and L. Dalton.
1982.
A comparison of saponin with other adjuvants for the potentiation of protective immunity by a killed Plasmodium yoelii vaccine in the mouse.
Parasite Immunol.
4:337-347[Medline].
|
| 14.
|
Molinari, J. L.,
D. Rodríguez,
P. Tato,
R. Soto,
F. Arechavaleta, and S. Solano.
1997.
Field trial for reducing porcine Taenia solium cysticercosis in Mexico by systematic vaccination of pigs.
Vet. Parasitol.
69:55-63[Medline].
|
| 15.
|
Mosmann, T. R.,
L. Li, and S. Subash.
1997.
Functions of CD8 T cells subset secreting different cytokine patterns.
Semin. Immunol.
9:87-92[Medline].
|
| 16.
|
Nascimento, E.,
J. O. Costa,
M. P. Guimaraes, and C. A. Tavares.
1995.
Effective immune protection of pigs against cysticercosis.
Vet. Immunol. Immunopathol.
45:127-137[Medline].
|
| 17.
|
Parkhouse, R. M., and L. J. Harrison.
1989.
Antigens of parasitic helminths in diagnosis, protection and pathology.
Parasitology
99:S5-S19.
|
| 18.
|
Rammensee, H. G.,
T. Friede, and S. Stevanovic.
1995.
MHC ligands and peptide motifs: first listing.
Immunogenetics
41:178-228[Medline].
|
| 19.
|
Ramos-Kuri, M.,
M. R. Montoya,
A. Padilla,
T. Govezensky,
M. Diaz,
E. Sciutto,
J. Sotelo, and C. Larralde.
1992.
Immunodiagnosis of neurocysticercosis.
Arch. Neurol.
49:633-636[Abstract/Free Full Text].
|
| 20.
|
Richards, F., Jr., and P. Schantz.
1991.
Laboratory diagnosis of cysticercosis.
Clin. Lab. Med.
11:1011-1028[Medline].
|
| 21.
|
Rickard, M. E., and J. F. Williams.
1982.
Hydatidosis/cysticercosis: immune mechanisms and immunization against infection.
Adv. Parasitol.
21:229-296[Medline].
|
| 22.
|
Sciutto, E.,
G. Fragoso,
L. Trueba,
D. Lémus,
R. M. Montoya,
M. L. Díaz,
T. Govezensky,
C. Lomeli,
G. Tapia, and C. Larralde.
1990.
Cysticercosis vaccine: cross-protecting immunity with T. solium antigens against experimental murine T. crassiceps cysticercosis.
Parasite Immunol.
12:687-696[Medline].
|
| 23.
|
Sciutto, E.,
A. Aluja,
G. Fragoso,
L. F. Rodarte,
M. Hernández,
M. N. Villalobos,
A. Padilla,
N. Keilbach,
M. Baca,
T. Govezensky,
S. Díaz, and C. Larralde.
1995.
Immunization of pigs against Taenia solium cysticercosis: factors related to effective protection.
Vet. Parasitol.
60:53-67[Medline].
|
| 24.
|
Sotelo, J.,
O. del Bruto, and G. Román.
1996.
Cysticercosis.
Curr. Clin. Trop. Infect. Dis.
16:240-259.
|
| 25.
|
Tam, J. P.
1994.
Immunization with peptide carrier complexes: traditional and multiple antigen peptide system, p. 83-115.
In
G. B. Wisdom (ed.), Peptide antigens. Oxford University Press, New York, N.Y.
|
| 26.
|
Tamburrini, A.,
M. A. Gomez Morales, and E. Pozio.
1995.
Development of an immunoenzyme test for the diagnosis of human cysticercosis using a heterologous antigen.
Parassitologia
37:195-198[Medline].
|
| 27.
|
Terrazas, L. I.,
R. Bojalil,
T. Govezensky, and C. Larralde.
1998.
Shift from an early protective TH1-type immune response to a late permissive TH2-type response in murine cysticercosis (Taenia crassiceps).
J. Parasitol.
84:74-81[Medline].
|
| 28.
|
Valdez, F.,
M. Hernández,
T. Govezensky,
G. Fragoso, and E. Sciutto.
1994.
Immunization against Taenia crassiceps cysticercosis. Identification of the most promising antigens in the induction of protective immunity.
J. Parasitol.
80:931-936[Medline].
|
Infection and Immunity, May 1999, p. 2522-2530, Vol. 67, No. 5
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Vazquez-Talavera, J., Solis, C. F., Terrazas, L. I., Laclette, J. P.
(2001). Characterization and Protective Potential of the Immune Response to Taenia solium Paramyosin in a Murine Model of Cysticercosis. Infect. Immun.
69: 5412-5416
[Abstract]
[Full Text]
-
Toledo, A., Fragoso, G., Rosas, G., Hernandez, M., Gevorkian, G., Lopez-Casillas, F., Hernandez, B., Acero, G., Huerta, M., Larralde, C., Sciutto, E.
(2001). Two Epitopes Shared by Taenia crassiceps and Taenia solium Confer Protection against Murine T. crassiceps Cysticercosis along with a Prominent T1 Response. Infect. Immun.
69: 1766-1773
[Abstract]
[Full Text]